

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/480,977	01/11/2000	PAUL J. GODOWSKI	P1084R1C1	5001
759	90 04/25/2002			
GENENTECH INC			EXAMINER	
ATTN DEIRDRE L CONLEY PH D 1DNA WAY			HUNT, JENNIFER ELIZABETH	
SOUTH SAN FRANCISCO, CA 940804990			ART UNIT	PAPER NUMBER
			1642	11
		DATE MAILED: 04/25/2002	!	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No. 09/480.977

Applicant(s)

0.077

Jennifer Hunt

Examiner

Art Unit

Godowski et al.

1642

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) X Responsive to communication(s) filed on <u>Dec 19, 2001</u> 2a) This action is **FINAL**. 2b) X This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11; 453 O.G. 213. Disposition of Claims ______ is/are pending in the application. 4) X Claim(s) 1, 4, and 39 4a) Of the above, claim(s) _______ is/are withdrawn from consideration. 5) Claim(s) 6) X Claim(s) 1, 4, and 39 is/are rejected. 8) Claims ______ are subject to restriction and/or election requirement. **Application Papers** 9) \square The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are objected to by the Examiner. 11) ☐ The proposed drawing correction filed on ______ is: a) ☐ approved b) ☐ disapproved. 12) The oath or declaration is objected to by the Examiner. Priority under 35 U.S.C. § 119 13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). *See the attached detailed Office action for a list of the certified copies not received. 14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e). Attachment(s) 15) Notice of References Cited (PTO-892) 19) Notice of Informal Patent Application (PTO-152) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 20) Other: 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s).

Application/Control Number: 09/480,977

Art Unit: 1642

Response to Amendment

1. Prosecution on the merits of this application is reopened on claims 1, 4, and 39 considered unpatentable for the reasons indicated below. The amendment filed December 19, 2001 has been entered.

Double Patenting

2. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321© may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

3. Claims 1, 4, and 39 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claim 1 of U.S. Patent No. 6,121,415. Although the conflicting claims are not identical, they are not patentably distinct from each other because both claim 1 of U.S. Patent No. 6,121,415, and the instant claims 1, 4, and 39 are drawn to a polypeptide comprising an amino acid sequence which encodes the EGF domain of SEQ ID

Application/Control Number: 09/480,977

Art Unit: 1642

NO:4, including a polypeptide which activates tyrosine phosphorylation of the ErbB4 receptor. While the instant claim 39 recites that the polypeptide must exhibit binding to the ErbB4 receptor, and not the ErbB2 or ErbB3 receptor, this would be an intrinsic property of a polypeptide which encodes the EGF domain of SEQ ID NO:4.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Hunt, whose telephone number is (703) 308-7548. The examiner can normally be reached Monday through Thursday 6:30am to 5:00pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Anthony Caputa can be reached at (703) 308-3995. The fax number for the group is (703) 305-3014 or (703) 308-4242.

Communications via internet e-mail regarding this application, other than those under 35 U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [anthony.caputa@uspto.gov].

All internet e-mail communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists the possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of U.S.C. 122. This is more clearly set

Application/Control Number: 09/480,977

Art Unit: 1642

forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist, whose telephone number is (703) 308-0196.

Jennifer Hunt

April 23, 2002

SHEELA HUFF PRIMARY EXAMINER